ClinicalTrials.gg
CompletedNCT06253195Updated Jun 10, 2026

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase 1 interventional study of BGB-43395 and Fulvestrant in Advanced Solid Tumor, Metastatic Solid Tumor and Hormone-receptor-positive Breast Cancer, sponsored by BeOne Medicines. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
302nd of 401
33 · median 90
Started
2024
with 44 others
Phase 1
93 of 485
47 open now
Registered
314th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 302nd largest by enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2024, is one of 93 in phase 1, and was the 314th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, as monotherapy or in combination with fulvestrant, letrozole, or other combination partners in Chinese participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced or metastatic solid tumors.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Hormone-receptor-positive Breast Cancer
  • Breast Cancer
  • Metastatic Breast Cancer
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • HER2-negative Breast Cancer

Keywords

  • advanced solid tumor
  • metastatic solid tumor
  • BGB-43395
  • breast cancer
  • HR+/HER2- breast cancer
  • hormone receptor positive breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1a (Dose Escalation): Participants with or cytologically confirmed locally advanced or solid tumors associated with CDK4 dependency, including HR+/- breast cancer. Participants must have received prior standard-of-care therapies for their disease, unless the therapy is not available or not tolerated, or is determined not appropriate based on the investigator's judgment.
  • Phase 1b (Dose Expansion): Participants with selected solid tumors including locally advanced or metastatic HR+/HER2- breast cancer.
  • Female participants with metastatic HR+/HER2- breast cancer will be required to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists such as goserelin or be .
  • Male participants with HR+/HER2- breast cancer will be required to have gonadal suppression using GnRH agonists when being treated with letrozole or fulvestrant.
  • Patients must have ≥1 per v1.1.
  • (ECOG) Performance Status ≤ 1.
  • Adequate organ function without symptomatic visceral disease.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy selectively targeting CDK4 (prior CDK4/6 inhibitor therapy is permitted).
  • Known or uncontrolled untreated .
  • Any ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
  • Uncontrolled diabetes.
  • Infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic COVID-19 infection. Patients receiving prophylactic antibiotics (eg, for prevention of urinary tract infection, , or for dental extraction) are eligible. Patients who have recovered from symptomatic COVID-19 infection can be rescreened for this study.
  • Untreated chronic or active infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Phase 1a: Dose Escalation

    Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole.

    Drug: BGB-43395 · Drug: Fulvestrant · Drug: Letrozole

  • Experimental
    Phase 1b: Dose Expansion

    The recommended dose for expansion (RDFE) for BGB-43395 in combination with fulvestrant from Phase 1a will be evaluated in HR+ breast cancer and selected tumor cohorts.

    Drug: BGB-43395 · Drug: Fulvestrant

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments as needed, and that meet protocol-defined dose-limiting toxicity (DLT) criteria.

    Time frame: Up to approximately 30 months

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395

    MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate. MAD is defined as the highest dose administered if MTD is not reached.

    Time frame: Up to approximately 30 months

  3. Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-43395

    RDFE of BGB-43395 alone or as part of combination therapies will be determined based upon the MTD or MAD.

    Time frame: Up to approximately 30 months

  4. Phase 1b: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Phase 1a: ORR

    ORR is defined as the percentage of participants who have confirmed CR or PR assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 30 months

  2. Phase 1b: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

    Time frame: Up to approximately 30 months

  3. Phase 1b: Number of Participants with AEs and SAEs

    Number of participants with AEs and SAEs including findings from physical examinations, ECGs, and laboratory assessments as needed.

    Time frame: Up to approximately 30 months

  4. Phase 1a and 1b: Duration of Response (DOR)

    DOR is defined as the time from the first determination of an objective response by the investigator using RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first.

    Time frame: Up to approximately 30 months

  5. Phase 1a and 1b: Time to Response (TTR)

    TTR is defined as the time from the date of the first dose of study drugs to the date of the first determination of objective response that is confirmed by a subsequent response as assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 30 months

  6. Phase 1b: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease assessed by the investigator using RECIST v1.1.

    Time frame: Up to approximately 30 months

  7. Phase 1b: Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks.

    Time frame: Up to approximately 30 months

  8. Phase 1a: Observed plasma maximum concentration (Cmax) of BGB-43395 and its metabolite

    Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)

  9. Phase 1a: Observed plasma trough concentration (Ctrough) of BGB-43395 and its metabolite

    Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)

  10. Phase 1a: Area under the concentration-time curve (AUC) of BGB-43395 and its metabolite

    Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)

  11. Phase 1a: Half-life (t1/2) of BGB-43395 and its metabolite

    Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)

  12. Phase 1b: Plasma concentrations of BGB-43395 and its metabolite

    Time frame: From Cycle 1 Day 1 up to Cycle 5 Day 1 (each cycle is 28 days)

07

Study locations

7 sites
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
    Guangzhou, Guangdong 510245, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200000, China
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2026, 24 months.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 24 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
Apr 1, 2024
Primary completionActual
Apr 23, 2026
CompletionActual
Apr 23, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06253195
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Apr 1, 2024
Primary completion
Apr 23, 2026
Completion
Apr 23, 2026
Last update
Jun 10, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK4 Inhibitor BGB-43395

Start the discussion